Avinger (NASDAQ:AVGR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR) in a research note released on Thursday. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $5.00 price objective on shares of Avinger in a research note on Thursday, March 21st.

Avinger Stock Performance

NASDAQ AVGR opened at $3.90 on Thursday. Avinger has a 1 year low of $2.50 and a 1 year high of $18.00. The business’s fifty day moving average is $3.46 and its two-hundred day moving average is $3.26. The stock has a market capitalization of $6.20 million, a P/E ratio of -0.15 and a beta of 1.22.

Avinger (NASDAQ:AVGR) last announced its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The business had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.52 million. On average, research analysts forecast that Avinger will post -2.08 earnings per share for the current year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.